CDK4/6 Inhibitor Sequencing and NCCN Guidelines in mBC

5. Frank Scimeca, PharmD, MBA, BCOP, leads a discussion on sequencing CDK4/6 inhibitors, comparing their side effect profiles, toxicity benefits, and progression-free survival (PFS) advantages. He emphasizes the need for additional biomarkers and clearer guidance from the NCCN to aid in selecting the most appropriate drug for each patient.